CervoMed Announced Oral Presentation At CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized Design Of Phase 2b Clinical Study Of Neflamapimod In Dementia With Lewy Bodies
Portfolio Pulse from Charles Gross
CervoMed Inc. (NASDAQ:CRVO) announced an oral presentation at the 16th Clinical Trials in Alzheimer's Disease (CTAD) conference, highlighting the neflamapimod clinical development program. The presentation included the RewinD-LB Phase 2b study design and supportive Phase 2a clinical data for the treatment of patients with dementia with Lewy bodies (DLB). The Phase 2b study has over 95% statistical power to meet its primary endpoint. New data shows that neflamapimod treatment significantly reduces a potential blood biomarker of DLB in patients without Alzheimer's-related co-pathology.
October 25, 2023 | 6:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CervoMed's presentation at CTAD highlighted the potential of neflamapimod in treating dementia with Lewy bodies. The Phase 2b study has over 95% statistical power to meet its primary endpoint, indicating a high likelihood of success.
The announcement of positive results from the Phase 2b study of neflamapimod is likely to boost investor confidence in CervoMed. The high statistical power of the study indicates a high likelihood of the drug meeting its primary endpoint, which could lead to regulatory approval and potential revenue generation for the company.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100